National Patient Safety Agency Alert 20 (2007) requires that information on how to prepare and safely administer injectable medicines is available at the point of care. This article describes the development of the Injectable Medicines Guide website, which is recommended in Alert 20 as a suitable source of information. Historically, individual hospitals have produced local guidelines resulting in much duplication of effort. The website was developed by liaising with a large number of hospitals across the UK to produce standardized information on intravenous (IV) medicine administration. The website can be tailored to reflect local needs, which would include those sections that are absolutely essential for safe administration of the medicine; but access to the full monograph can still be easily obtained. In addition, organizations can link locally-produced IV medicine-related guidelines to individual monographs. For organizations that produce their own locally-prepared injectable medicines guide, it is possible to add it to the website in such a way that it can be viewed with an appropriate link in place to the Injectable Medicine Guide website monograph. The Intensive Care Society (2010) has issued a statement supporting the adoption of standard concentrations for 16 medications commonly used in critical care and the website is being updated to reflect this statement. Specialist mental health pharmacists are preparing monographs on medicines commonly administered by intramuscular (IM) injection in mental health practice. These are planned for release in the autumn of 2010. Currently, a robust source of funding is not available to underpin the production of the website. Appropriate funding would allow it to become universally available across the UK, without the need for password-protection. The website could then more easily become embedded in computerized prescribing systems
I
n 2007, the National Patient Safety Agency (NPSA) issued an alert promoting the safer use of injectable medicines, (NPSA Alert 20). The alert requires that information on how to prepare and safely administer injectable medicines be available at the point of care, and the Injectable Medicines Guide website was recommended as a suitable source of this information. This article describes the evolution of the Injectable Medicines Guide website and provides details on how to access and use it.
Birth of the Injectable Medicines Guide website
Historically, hospital pharmacists have been frequently asked for advice on the administration of injectable medicines and the appropriate interpretation of manufacturers' literature. In an attempt to minimize repetitive queries and standardize advice given, many pharmacy departments produced local guidelines on the intravenous (IV) administration of commonly used medicines. These local guidelines were designed to ensure that accurate information was readily available at ward level, and the use of a standard format and writing style was an attempt to reduce the chance of misinterpreting the information provided.
While local guidelines, often produced as loose-leaf folders, reduced some risks associated with injectable medicines, they also introduced a new risk. The guidelines required regular updating and it was difficult to ensure that old paper-based guidelines were removed from clinical areas when a new edition was issued. There was a risk that staff might work from outdated guidelines.
It also became clear that hospitals throughout the UK were undertaking similar projects and much of the work was being duplicated. To address this, around 15 years ago a group of hospital pharmacists established the Intravenous Drug Administration Group. The group liaised with a large number of hospitals to produce standardized information on IV drug administration; the information was published on a website and became available for use across the UK. The Injectable Medicines Guide website was born.
Content of the Injectable Medicines Guide
The website contains monographs for most medicines given by the IV route (approximately 300 medicines), with the exception of cytotoxic agents. Both licensed and unlicensed medicines are included.
The website is not an adult-only initiative. Each monograph contains information pertinent to children if administration is different from adults. IV medicines specific to paediatrics and neonatology have their own monographs. The website has a 'Documents and links' page, which includes links to useful background information relating to injectable medicines, The example calculation should only be used to check that the infusion rate calculated 4 for a specific patient is in the correct range. Doses given in this section are just an example and should not be used as a reference for prescribing or checking the prescription. An electronic calculator is being added to this section Flushing Sodium chloride 0.9% is recommended as a flush for most drugs. In a very few 4 circumstances where it cannot be used, glucose 5% is recommended as an alternative Adverse effects relevant to the route This section includes details of adverse effects that may occur acutely, either during 4 of administration and suggested or very shortly after, administration of a medicine by the intravenous route and monitoring suggested appropriate monitoring
Link to BNF interactions An electronic link to the 'Interactions' section of the BNF is included if appropriate 3
Extravasation Potential consequences of extravasation are detailed 3
Compatibility information useful When medicines are stated as compatible, it is assumed that they meet in the 3 in clinical practice administration set close to the cannula insertion site. This section also details of suitable diluents other than sodium chloride 0.9% or glucose 5%, e.g. Hartman's solution Special handling precautions Handling precautions required in addition to wearing gloves and an apron, are included 3
Sodium content (mmol) 3
Osmolarity/osmolality Infiltration of solutions with an osmolarity greater than that of plasma (greater than 3 290mOsmol/L) may cause tissue damage. It is recommended that if the osmolarity is greater than 600mOsmol/L, the medicine should be infused via a central venous catheter pH:
Medicines with a high (greater than 9) or low (less than 5) pH are likely to cause tissue 3 damage if extravasation occurs. It is recommended that these products are administered via a central venous catheter
Other comments
Highlights any SPC changes or significant NPSA/MHRA alerts that have become available 3 since the monograph was last published Infusion pump to use for the infusion Infusion pumps are designed for a variety of clinical applications and their performance 3 therapy category characteristics vary. There are three therapy categories (A, B and C) and they determine the performance and safety parameters of the infusion pump required to deliver a particular medicine Pharmacists are expected to obtain comments on the content and ease of use of the monographs they write from nursing and medical staff working in their organization. All new and updated monographs are checked for accuracy and clarity by a pharmacist from one of the regional NHS Medicines Information Centres. Manufacturers are also asked to comment on draft monographs that have been prepared for their own products. The Intensive Care Society (ICS) (2010) has issued a statement supporting the adoption of standard concentrations for 16 medications commonly used in critical care. Monographs relating to these medicines are being updated to reflect the recommended standard concentrations.
Monograph content
The content of each monograph is outlined in Table 1 . In brief: ■ Each monograph describes the most appropriate method of preparation and administration of the injectable medicine, and details adverse effects that may be pertinent to the route of administration ■ The monographs do not provide dosage information.
Responsibility for dose lies clearly with the prescriber and is patient-specific. However, monographs for medicines given by continuous infusion contain example calculations; an online electronic calculator is under development ■ When viewing a monograph on the website, 'help' can be obtained by clicking on a monograph heading. The help box obtained describes in detail how best to interpret the information contained in that section ■ Each monograph contains electronic links to the relevant sections of the British National Formulary and links to any available Summary of Product Characteristics and patient information leaflets produced by the manufacturer.
Using the Injectable Medicines Guide website
Internet access to the Guide requires a user name and password. However, once the guide is installed on a local trust network the website can be made available without the need to log in. The website can be tailored to local needs. For example, a 'condensed' version of a monograph can be created. The condensed version includes those sections that are absolutely essential for safe administration of the medicine, but access to the full monograph can still be easily obtained. The monographs have four different levels of access (Table 1) injectable medicines guide, it is possible to add the local guide to the website in such a way that it can be viewed with an appropriate link in place to the Injectable Medicine Guide monograph. Figure 2 demonstrates an Injectable Medicines Guide website view containing a local guide entry; there is a link at the bottom to the relevant Injectable Medicines Guide website monograph.
Usage figures for the Injectable Medicines Guide
Use of the website has dramatically increased over the past few years. The website is used during the day and night as shown in Figure 3 , and monthly in Figure 4 .
Availability of the website
The website is available free of charge to all NHS organizations that contribute to its production. Organizations unable to contribute can subscribe to the website; any income generated is used to support its production. The website is available as an electronic 'link' via the National Infusion and Vascular Access Society (NIVAS) website. A demonstration version can be viewed at http://medusa.wales.nhs.uk/ (from NHSnet websites only) or www.injguide.nhs.uk/ (from any internet connection) using the following logon details: Username: ivgdemo; Password: bolus7. Feedback on the website from users is actively sought, and will be used to guide future changes.
Future developments
For the future the following developments need to be explored: ■ The website is produced with only limited multidisciplinary input. Strong links with all users of injectable medicines need to be established to ensure that untapped multidisciplinary expertise is reflected in the monographs ■ A robust source of funding is required to underpin the production of the website. This would allow it to become universally available across the UK without the need for password protection. The website could more easily then become embedded in computerized prescribing systems ■ Expanding the website to include other inherently 'high-risk' injectable preparations, e.g. intrathecal injections ■ Appropriate information on any imported product with a foreign language insert needs to be made available via the website as soon as a manufacturer supply problem occurs with a UK product. This will help to ensure that staff in clinical areas can safely prepare and administer the medicine ■ Further work on establishing standard concentrations for commonly used infusion products not covered in the Intensive Care Society statement is required. Specialist mental health pharmacists are currently preparing monographs on medicines commonly administered by intramuscular (IM) injection in mental health practice. These are planned for release in the autumn of 2010.
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Intensive Care Society ( The need for different levels of access has emerged from user feedback. Some users find the entire monograph overwhelming and just want the minimum information for the safe administration of the drug, while other users want access to more detailed information. Nurses can choose their level of access, while pharmacists are expected to use level 2 access to ensure they have enough information to provide colleagues with clinical advice on the drug to be administered.
Monographs can be printed if access to computers is limited in the clinical area. The monograph sections included in any printed versions can also be adapted to local requirements; the condensed or the full version of the monograph can be printed.
Organizations can link locally-produced IV medicine-related guidelines to individual monographs to create a version of the website more suitable for local needs (Figure 1 ): ■ The pink box can be used for local information that an organization may want to add to the top of every monograph on the website; for example, a trust logo or links to local IV medicine administration guidelines/resuscitation guidelines/ treatment of anaphylaxis guidelines ■ The purple box can be used for local information that an organization may want to add to the top of one particular monograph only: for example, to highlight any differences between local practice and information provided in the national monograph, or a link to a document about a medicine which appears on the local intranet; all antibiotic monographs might be linked to local anti-infective guidelines, for example. For organizations that still have their own locally prepared
